BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31924529)

  • 1. High-intensity Focused Ultrasound for the Treatment of Prostate Cancer: A National Cohort Study Focusing on the Development of Stricture and Fistulae.
    Dosanjh A; Harvey P; Baldwin S; Mintz H; Evison F; Gallier S; Trudgill N; James ND; Sooriakumaran P; Patel P
    Eur Urol Focus; 2021 Mar; 7(2):340-346. PubMed ID: 31924529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of high intensity focused ultrasound treatment of prostate cancer: early Canadian experience at a single center.
    Elterman DS; Barkin J; Radomski SB; Fleshner NE; Liu B; Bensimon K; Arora S; Robinette M; Finelli A
    Can J Urol; 2011 Dec; 18(6):6037-42. PubMed ID: 22166332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-intensity focused ultrasound for localized prostate cancer: initial experience with a 2-year follow-up.
    Challacombe BJ; Murphy DG; Zakri R; Cahill DJ
    BJU Int; 2009 Jul; 104(2):200-4. PubMed ID: 19220245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medium-term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort.
    Dickinson L; Arya M; Afzal N; Cathcart P; Charman SC; Cornaby A; Hindley RG; Lewi H; McCartan N; Moore CM; Nathan S; Ogden C; Persad R; van der Meulen J; Weir S; Emberton M; Ahmed HU
    Eur Urol; 2016 Oct; 70(4):668-674. PubMed ID: 26951947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer.
    Cordeiro ER; Cathelineau X; Thüroff S; Marberger M; Crouzet S; de la Rosette JJ
    BJU Int; 2012 Nov; 110(9):1228-42. PubMed ID: 22672199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically significant urethral stricture and/or subclinical urethral stricture after high-intensity focused ultrasound correlates with disease-free survival in patients with localized prostate cancer.
    Komura K; Inamoto T; Black PC; Fujisue Y; Katsuoka Y; Watsuji T; Azuma H
    Urol Int; 2011; 87(3):276-81. PubMed ID: 21912100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.
    Guillaumier S; Peters M; Arya M; Afzal N; Charman S; Dudderidge T; Hosking-Jervis F; Hindley RG; Lewi H; McCartan N; Moore CM; Nigam R; Ogden C; Persad R; Shah K; van der Meulen J; Virdi J; Winkler M; Emberton M; Ahmed HU
    Eur Urol; 2018 Oct; 74(4):422-429. PubMed ID: 29960750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transrectal high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer: review of technical incidents and morbidity after 5 years of use.
    Ripert T; Azémar MD; Ménard J; Bayoud Y; Messaoudi R; Duval F; Staerman F
    Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):132-7. PubMed ID: 20048758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-intensity focused ultrasound therapy for clinically localized prostate cancer.
    Lee HM; Hong JH; Choi HY
    Prostate Cancer Prostatic Dis; 2006; 9(4):439-43. PubMed ID: 16847468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
    Asimakopoulos AD; Miano R; Virgili G; Vespasiani G; Finazzi Agrò E
    Urol Oncol; 2012 Sep; 30(5):577-83. PubMed ID: 21292508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer.
    Kanthabalan A; Peters M; Van Vulpen M; McCartan N; Hindley RG; Emara A; Moore CM; Arya M; Emberton M; Ahmed HU
    BJU Int; 2017 Aug; 120(2):246-256. PubMed ID: 28258616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Transurethral resection of prostate just following high intensity focused ultrasound in localized prostate cancer--trial for early removal of the urethral catheter].
    Otsuki H; Sumitomo M; Umeda S; Shirotake S; Tobe M; Ito K; Asano T; Nagakura K; Hayakawa M
    Hinyokika Kiyo; 2008 Mar; 54(3):189-95. PubMed ID: 18411774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series.
    Ahmed HU; Zacharakis E; Dudderidge T; Armitage JN; Scott R; Calleary J; Illing R; Kirkham A; Freeman A; Ogden C; Allen C; Emberton M
    Br J Cancer; 2009 Jul; 101(1):19-26. PubMed ID: 19513068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients.
    Crouzet S; Chapelon JY; Rouvière O; Mege-Lechevallier F; Colombel M; Tonoli-Catez H; Martin X; Gelet A
    Eur Urol; 2014 May; 65(5):907-14. PubMed ID: 23669165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes.
    Pfeiffer D; Berger J; Gross AJ
    BJU Int; 2012 Dec; 110(11):1702-7. PubMed ID: 22928703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Location of residual cancer after transrectal high-intensity focused ultrasound ablation for clinically localized prostate cancer.
    Boutier R; Girouin N; Cheikh AB; Belot A; Rabilloud M; Gelet A; Chapelon JY; Rouvière O
    BJU Int; 2011 Dec; 108(11):1776-81. PubMed ID: 21711432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT.
    Hamdy FC; Elliott D; le Conte S; Davies LC; Burns RM; Thomson C; Gray R; Wolstenholme J; Donovan JL; Fitzpatrick R; Verrill C; Gleeson F; Singh S; Rosario D; Catto JW; Brewster S; Dudderidge T; Hindley R; Emara A; Sooriakumaran P; Ahmed HU; Leslie TA
    Health Technol Assess; 2018 Sep; 22(52):1-96. PubMed ID: 30264692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience.
    Reddy D; Peters M; Shah TT; van Son M; Tanaka MB; Huber PM; Lomas D; Rakauskas A; Miah S; Eldred-Evans D; Guillaumier S; Hosking-Jervis F; Engle R; Dudderidge T; Hindley RG; Emara A; Nigam R; McCartan N; Valerio M; Afzal N; Lewi H; Orczyk C; Ogden C; Shergill I; Persad R; Virdi J; Moore CM; Arya M; Winkler M; Emberton M; Ahmed HU
    Eur Urol; 2022 Apr; 81(4):407-413. PubMed ID: 35123819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2n0m0 localized prostate cancer: a preliminary report.
    Uchida T; Sanghvi NT; Gardner TA; Koch MO; Ishii D; Minei S; Satoh T; Hyodo T; Irie A; Baba S
    Urology; 2002 Mar; 59(3):394-8; discussion 398-9. PubMed ID: 11880077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-intensity Focused Ultrasound (HIFU) as salvage therapy for radio-recurrent prostate cancer: predictors of disease response.
    Dason S; Wong NC; Allard CB; Hoogenes J; Orovan W; Shayegan B
    Int Braz J Urol; 2018; 44(2):248-257. PubMed ID: 29211405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.